Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Strong Cash Position at exit 2020

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Nov 16, 2020 4:03pm

123 Views

Post# 31908503

RE:RE:Strong Cash Position at exit 2020

The .expiry dates extend well into the future.
So, a merger or prospective buyer in the Canadian Pharma market could make use of these for an extended period.

How long will depend on profits as higher profits..eg Bausch..could take full advantage..

ie,,utilization rate is dependent on magnitude of profitability

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?